AD represents approximately 10% of overall healthcare spend in the US, a penetration that is expected to deepen as an aging population and improved medicine leads to increased diagnoses. Healthcare spending in the US ranks higher than that of any other country, spending roughly $2 trillion, or 18% of GDP, on healthcare. In 2012, 15.4 million caregivers provided an estimated 17.5 billion hours of unpaid care, valued at more than $216 billion beyond the actual healthcare expenses. AD represents a large portion of this capital expenditure. It is estimated that the cost of caring for people with AD and other dementia's will rocket northwards from an estimated $203 billion in 2013 to a projected $1.2 trillion per year by 2050, with Medicare covering approximately 70% of costs.
The Company has estimated that peak sales for LymPro will exceed $500 million. On June 13, 2013 , the Company entered into a Laboratory Services Agreement with Becton Dickinson for the development of LymPro using BD Biosciences Custom Technology Team, and LymPro development remains on track to initiate a pivotal clinical study in early 2014 to support commercial launch of LymPro as a Laboratory-Developed Test ("LDT") under the Clinical Laboratory Improvements Act ("CLIA") in the second half of 2014.